# Efficacy and Safety Study of Eprotirome in HeFH Patients Who Are on Optimal Standard of Care

Study · id `cardio:ct-nct01410383` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01410383](<https://clinicaltrials.gov/study/NCT01410383>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01410383

Browse, organ or system: Heart; Metabolism  
Browse, condition area: Risk and prevention; Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 236 participants.

## Technical summary

Registry record NCT01410383. Randomized; triple masking; primary purpose treatment. Start 2011-10 (registry gives no type); primary completion 2013-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 236 participants (enrolled count; ClinicalTrials.gov record NCT01410383, source copy `cardio:ctgov-nct01410383-2012-09-03`, retrieved 2026-10-26)
- Start date: 2011-10 (registry gives no type) (ClinicalTrials.gov record NCT01410383, source copy `cardio:ctgov-nct01410383-2012-09-03`, retrieved 2026-10-26)
- Primary completion: 2013-10 (anticipated) (ClinicalTrials.gov record NCT01410383, source copy `cardio:ctgov-nct01410383-2012-09-03`, retrieved 2026-10-26)
- Completion: 2014-10 (anticipated) (ClinicalTrials.gov record NCT01410383, source copy `cardio:ctgov-nct01410383-2012-09-03`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01410383-2012-09-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety Study of Eprotirome in HeFH Patients Who Are on Optimal Standard of Care
- Acronym: AKKA
- Condition: Heterozygous Familial Hypercholesterolaemia
- Intervention (Drug): Placebo
- Intervention (Drug): Eprotirome
- Intervention (Drug): Eprotirome
- Lead sponsor: Karo Bio AB
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study (`cardio:pubmed-24731671`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 242bf41379465422a12d621fb6579350f1388d5cebde618d351d9484906769e3
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
